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It’s Good to Have a Choice; Now Let’s Get More Data: Response
Symptom Index for Patients with Primary Brain Tumors”We very much appreciate Armstrong et al.’s closing endorsement
of our questionnaire [1], especially as they developed and vali-
dated a “competing” instrument. With regard to the concerns
raised in the letter, we stand behind our statements in the article,
and clarify our perspective.
Their ﬁrst concern relates to the people one uses to develop
initial item content. We never stated that the development of
M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-
BT) excluded patients. However, we note that Armstrong et al. [2]
included only two patients (and two caregivers) in their content
validity exercise. When it comes to concept elicitation methodol-
ogy, this is limited representation by any standard. Yet, Arm-
strong et al. can take comfort in the high degree of similarity in
item content with the 24-item National Comprehensive Cancer
Network/Functional Assessment of Cancer Therapy-Brain Symp-
tom Index (NFBrSI-24), which included 50 patients in its concept
elicitation (content validity) phase. Our colleagues also question
our claim that this is the ﬁrst instrument developed speciﬁcally
for advanced disease. We do not know the disease stage of the
two people mentioned above for concept elicitation, but we do
note that more than one-third of the patients in the validation
article had grades I to II disease [3]. It is unclear to which extent
this limited disease, good performance status group might have
inﬂuenced their content validity index. Our focus was solely on
patients with grades III to IV disease, which we had made clear.
Armstrong et al. make a conceptual distinction between
quality-of-life measures and symptom measures, a distinction
they elaborate on in their 2006 article. We do not share this
perspective, and we can ﬁnd no evidence in the literature for it.
Health-related quality-of-life (HRQOL) measures—and in particular
the European Organization for Research and Treatment of Cancer
and Functional Assessment of Cancer Therapy (FACT) HRQOL
measures—include symptoms and their impact on function and
well-being. They add to this a broader range of content regarding
well-being. Similarly, by adding the general impact of symptoms
on function, well-being, and life enjoyment, the MDASI itself is
more than a symptom measure. The similarities of these instru-
ments are far greater than their differences. What distinguishes the
FACT panel of questionnaires from the others (MDASI and the
European Organization for Research and Treatment of Cancer) is its
scoring routine that summarizes together the symptoms, burdens,
and perspectives of people across physical, mental, and social
functioning. This has been both a strength and a weakness of the
FACT system. Many symptoms included in general and disease-cial Support: This project was supported by Am
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ceuticals.speciﬁc conceptions of HRQOL are embedded in FACT subscales
that do not lend themselves easily to articulating the symptom
impact of a treatment, even thoughmost of the relevant symptoms
are indeed in the questionnaire. The NFBrSI-24 now provides a
symptom-focused administration and scoring option for people
interested in using the FACT system in their clinical research.
We appreciate the opportunity to clarify our position on 0 to
10 rating scales. We do not recommend them, nor does the
National Institutes of Health Toolbox or the Patient-Reported
Outcomes Measurement Information System group (PROMIS). In
both the NIH Toolbox and the PROMIS, the only 0 to 10 rating
scale used is for pain intensity and it is being used because it is
the strong preference of the pain research community. Faced
with an entrenched position of opinion leaders, PROMIS and
Toolbox were compelled to overlook the measurement problems
associated with 0 to 10 scales, and the lack of evidence for their
preference by patients themselves, particularly when bridging
across cultures. Armstrong et al. are correct when they cite that 0
to 10 ratings are not evenly distributed along an item response
theory measurement continuum. A bigger concern is that a 0 to
10 rating scale often produces a disordering of categories along
the continuum [4], probably because 11 categories are more than
most human judgment capabilities can manage when answering
a question. This adds noise to measurement. We caution our-
selves and others against overgeneralizing from a long legacy of
pain measurement research when moving to the measurement
of other symptoms that can have different severity, course,
pattern, and impact on functioning and well-being.
We are pleased to see that our colleagues have apparently
changed their 2006 position [3] on the preference for 24-hour over
7-day recall, and note the increasing evidence in support of the
validity of the 7-day recall period, noting again that it enables
more time for a symptom/concern to be experienced. We look
forward to reading their new article on this, and also point out
other articles from the same group they cited in 2006 [5], which
adds to an increasing database in support of substantial associa-
tion between averaged daily ratings and 7-day recall [6–8].
Finally, with regard to the comparisons made between the
NFBrSI-24 and the MDASI-BT, we agree that there are more
similarities than there are differences. We see this as positive,
lending support to both. Judgments about redundancy and where
to draw the line for inclusion/exclusion are difﬁcult and require
careful consideration. Minor differences will always occur, and
probably have minimal to no effect on the bottom line. Asgen, AstraZeneca Pharmaceuticals, Bayer, Bristol-Myers Squibb,
erck & Company, Novartis, Ortho Biotech, Pﬁzer, Sanoﬁ-Aventis,
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that uses the word “symptom” in its title can be debated. It could
be debated ad nauseum (a symptom, incidentally), but we prefer
not to engage in this debate. The NFBrSI-24 includes questions
that are not symptoms, because we are committed to measuring
“symptoms and concerns” that are most important to patients.
We rely on patients to tell us what is important and on clinical
experts to help us separate from the list of 24 items those that
should be scored as “disease-related symptoms.” The other 12 are
treatment adverse effects and more general questions about
functioning and well-being. Similarly, the MDASI-BT asks about
mood, work, walking, general activities, social relationships, and
life enjoyment. Given that the patient must aggregate across a
wide range of symptoms when responding, one could debate
whether these are symptom versus more general function and
well-being items.
In closing, we encourage investigators who do not have a vested
interest in either of these instruments to compare their performance
in longitudinal research with patients with advanced brain tumor.
We suspect they will learn that both are quite useful, and more
similar than different. In the meantime, it is nice to have a choice.
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